91.5%
tumour-associated HLA-A*02 LOHunresectable advanced or metastatic solid tumourstumourBASECAMP-1TmodTempusDENALI-1
…r the BASECAMP-1 study; of these, 30 consented participants had tumour-associated HLA-A*02 LOH and met other study eligibility criteria. Using the Aware progr…